Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.
The proven clinical efficacy of the CB(1) cannabinoid receptor antagonist rimonabant in both obesity and smoking cessation and its therapeutic potential in other disorders has given a tremendous impetus to the discovery of novel CB(1) antagonists. The number of disclosed patents wherein novel chemical entities having CB(1) antagonistic or inverse agonistic properties have been claimed has exploded. Besides novel compound classes that were identified in screening, rational medicinal chemistry approaches such as conformational constraint and scaffold hopping have been successfully applied. CB(1) receptor modelling has provided insight into crucial receptor-ligand interaction points thereby leading to a general CB(1) inverse agonist pharmacophore model.
Lange
Jos H M
JH
Solvay Pharmaceuticals, Research Laboratories, C. J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands. jos.lange@solvay.com
Kruse
Chris G
CG
D002626:Chemistry, Pharmaceutical / Q000639:trends*; D006801:Humans; D008968:Molecular Conformation; D009765:Obesity / Q000188:drug therapy; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry; D016540:Smoking Cessation; D013329:Structure-Activity Relationship
D043884:Receptor, Cannabinoid, CB1